Krystal Biotech Inc (KRYS)

Nov 2, 2026

Krystal Biotech reported strong Q3 2026 results with Vyjuvek revenue of $127.3 million, a 30% increase year-over-year, and ended the quarter with $1.2 billion in cash. The company announced a $400 million share repurchase program and highlighted significant international expansion for Vyjuvek, particularly in Germany, France, and Japan, with successful pricing negotiations in key European markets. Krystal Biotech also provided updates on its clinical pipeline, including encouraging results from the Gorlin syndrome study and progress in Hailey-Hailey disease, cystic fibrosis, and other programs, while revising full-year non-GAAP R&D and SG&A guidance downwards.

Nov 2, 2026

Krystal Biotech reported a 30% year-over-year increase in third-quarter VYJUVEK net revenue, reaching $127.3 million, with a 94% gross margin. Despite the revenue growth, net income declined to $63.1 million. The company authorized a $400 million share repurchase program, concluded pricing negotiations for VYJUVEK in Germany and Italy, and advanced its clinical development programs.